SELLAS Life Sciences Group, Inc.
NASDAQ:SLSBiotechnology
+$0.31 today
- Market cap
- $3.66B
- Beta
- 2.53
- P/E (TTM)
- -47.3
- EPS (TTM)
- -$0.17
Volume 35.53M
Average 7.79M
SLS Selling, General & Admin
Overhead costs of running the business, including sales, marketing, management, and administrative staff.
SELLAS Life Sciences Group, Inc.NASDAQ: SLS
Selling, General & Admin · Q3 FY2026 · quarter ended Sep 2026
Selling, general & admin growth accelerates
Q3 FY2026 selling, general & admin of $4.28M rose 49.3% year over year, ahead of the +45.3% change in trailing-twelve-month selling, general & admin. Sequentially, it fell 1.8% from the prior quarter. Over 3 fiscal years it compounded at -0.9% a year.
Context
- Selling, general & admin increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether selling, general & admin reaches the consensus estimate from 1 analysts of $123.37M (+907.0%) for the fiscal year ending Dec 2026, a step up from the -1.3% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterSep 2026
- $4.28M-1.8% QoQ
- Last fiscal yearDec 2025
- $12.25M-1.3% YoY
- LTMSep 2026
- $16.29M+45.3% YoY
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Selling, General & Admin history
USD · from the income statement
- Latest · FY2025
- 12.25M USD
- Year-over-year change
- -1.3%
- 4-year CAGR
- +2.0%
| Period | Period end | Selling, General & Admin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 12.25M | -1.3% |
| FY2024 | 2024-12-31 | 12.42M | -10.4% |
| FY2023 | 2023-12-31 | 13.86M | +10.2% |
| FY2022 | 2022-12-31 | 12.58M | +11.1% |
| FY2021 | 2021-12-31 | 11.32M | — |
Selling, General & Admin vs competitors
How SLS compares with its peers on the latest reported figures
- Peers report in different currencies, so selling, general & admin is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +45.3% is the 6th highest of 11, against a peer median of +44.4%.
- Over three fiscal years its annual growth of -0.9% compares with a peer median of +11.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $1.4B USD | +8.2% | +11.2% | 24.0% | |
AAPGAscentage Pharma Group International | FY2025 | CN¥522.67M CNY | +36.4% | +16.8% | 93.6% |
| LTM Aug 2026 | $78.21M USD | +57.0% | +11.6% | 11.1% | |
| LTM Mar 2026 | $69.19M USD | +65.4% | +42.7% | 30.7% | |
| LTM Sep 2026 | $64.15M USD | +52.3% | +47.5% | — | |
| LTM Mar 2026 | $38.15M USD | -27.9% | -12.7% | 24.3% | |
| LTM Mar 2026 | $34.4M USD | -16.4% | -5.4% | 98.7% | |
| LTM Mar 2026 | $29.66M USD | +100.0% | +10.0% | 249.6% | |
| LTM Mar 2026 | $27.19M USD | +59.1% | +55.2% | — | |
| LTM Mar 2026 | $21.38M USD | -22.5% | -9.9% | 127.9% | |
| LTM Sep 2026 | $16.29M USD | +45.3% | -0.9% | — | |
| Peer median (excluding SLS) | — | +44.4% | +11.4% | 62.2% | |
Competitors are the stored peer set for SLS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 7.6M | 1M | 0 | 0 | 0 |
| Cost of Revenue | 200K | 100K | 0 | 0 | 0 |
| Gross Profit | 7.4M | 900K | 0 | 0 | 0 |
| Gross Margin | 97.4% | 90.0% | — | — | — |
| Research & Development | 21.37M | 30.27M | 24.01M | 19.1M | 16.02M |
| Selling, General & Admin | 11.32M | 12.58M | 13.86M | 12.42M | 12.25M |
| Operating Expenses | 32.69M | 42.85M | 37.87M | 31.51M | 28.27M |
| Depreciation & Amortization | 1.27M | 457K | 37.87M | 31.51M | 0 |
| EBITDA | (18.32M) | (31.49M) | 529K | 632K | (26.86M) |
| EBITDA Margin | -241.1% | -3149.3% | — | — | — |
| Operating Income | (25.29M) | (41.95M) | (37.87M) | (31.51M) | (28.27M) |
| Operating Margin | -332.8% | -4195.0% | — | — | — |
| Interest Income | 6K | 317K | 525K | 632K | 1.41M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 4.36M | 649K | 529K | 632K | 1.41M |
| Income Before Tax | (20.94M) | (41.3M) | (37.34M) | (30.88M) | (26.86M) |
| Pre-Tax Margin | -275.5% | -4130.1% | — | — | — |
| Income Tax Expense | (237K) | 0 | 0 | 0 | 0 |
| Net Income | (20.7M) | (41.3M) | (37.34M) | (30.88M) | (26.86M) |
| Net Margin | -272.4% | -4130.1% | — | — | — |
| EPS (Basic) | (1.34) | (2.13) | (1.34) | (0.50) | (0.25) |
| EPS (Diluted) | (1.34) | (2.13) | (1.34) | (0.50) | (0.25) |
| Weighted Avg Shares | 15.48M | 19.4M | 27.78M | 61.2M | 109.05M |
| Weighted Avg Shares (Diluted) | 15.48M | 19.4M | 27.78M | 61.2M | 109.05M |
SELLAS Life Sciences Group, Inc.
NASDAQ:SLS
Intrinsic Alpha fair value
Locked
Current Price
$17.95
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.